Understanding GLP-1 Receptor Agonist Clinical Evidence: What to Know
GLP-1 receptor agonist discontinuation is a common pattern with important clinical implications. Understanding this behavior helps clinicians manage treatment persistence and weight regain. This clinical evidence guides family medicine providers in…
Medical Cannabis Authorization Linked to Modestly Higher Heart Failure Risk in Large Ontario Study
This Ontario cohort study examines medical cannabis cardiovascular safety, finding a modestly higher heart failure risk among authorized patients. The hazard ratio was 1.15, indicating a 15% increased risk for heart failure-related events. These findings…
Cannabis Use Linked to Increased Pain Interference and Depression in Older Adults
Cannabis use older adults depression pain was linked to more pain interference and depressive symptoms in a longitudinal observational study. The small cannabis-using subgroup limits causal conclusions. These findings highlight the need for cautious…
GLP-1 Weight Loss Cardiovascular Evidence in Women’s Health
GLP-1 receptor agonist women health benefits include improved insulin resistance and metabolic regulation in hormonal conditions. This class of drugs shows cardiovascular evidence supporting their use in reproductive-age women. Careful clinical…
GLP-1 Receptor Agonist Clinical Evidence: Muscle Loss Risk
GLP-1 receptor agonist muscle loss risk is a significant clinical concern during weight loss therapy. Research shows that these medications cause loss of skeletal muscle alongside fat. Understanding this risk helps clinicians optimize patient care with…
GLP-1 Receptor Agonist Discontinuation: What the Evidence Shows
GLP-1 receptor agonist discontinuation effects include significant weight regain and metabolic changes. Understanding these effects is crucial for clinicians managing obesity treatment. This evidence highlights the need for long-term therapy planning.
GLP-1 Receptor Agonist Clinical Evidence: Lean Mass Study
This study examines GLP-1 receptor agonist lean mass preservation during weight loss therapy. Semaglutide shows superior muscle mass protection compared to tirzepatide. Understanding lean mass outcomes is crucial for personalized obesity treatment.
GLP-1 Receptor Agonist Data: Joint Replacement Outcomes
GLP-1 receptor agonist joint replacement outcomes reveal important benefits for patients with obesity and knee osteoarthritis. Weight loss from semaglutide or tirzepatide can reduce the need for total knee arthroplasty. These outcomes support GLP-1…
Large Study Finds No Evidence Cannabis Use Accelerates Cognitive Decline or Raises Dementia Risk in Older Adults
This study on cannabis cognitive decline dementia risk older adults found no significant association between cannabis use and accelerated cognitive decline or increased dementia risk. The research analyzed large population cohorts and used Mendelian…
Cannabis Extract Linked to Pain Reduction in Small Observational Study—But Proof of Causation Is Absent
The cannabis extract chronic pain ESCAPE study observed reduced pain scores in patients using a 1:1 THC:CBD formulation. This observational study highlights potential benefits but cannot prove causation. Careful interpretation is needed due to study…
